한글목차

정밀 종양학 동향 및 전망

세계 정밀 종양학 시장은 2024년부터 2030년까지 9.0%의 CAGR을 기록하며 2030년까지 약 1,828억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 기술 발전, 암 환자에서 부작용을 최소화하면서 효과적인 결과를 제공하는 진단 제품에 대한 수요 증가, 특정 약물 내성 문제에 대한 대응입니다. 세계 정밀 종양학 시장의 미래는 병원 및 진단 실험실, 제약 및 생명공학 기업, 의료 데이터 기업 등 다양한 분야에서 유망한 기회를 제공할 것으로 예상됩니다.

Lucintel의 예측에 따르면, 암 조기 개입 및 치료 수요 증가, 영상 진단 및 검사 기술 향상, 진단 결과에 기반한 맞춤형 의약품에 대한 수요 증가로 인해 진단 분야가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

이 시장 중 병원 및 진단 검사실은 전 세계 진단 시설의 확대로 인해 가장 큰 부문으로 남아 있으며, 이 분야의 성장을 가속화할 것으로 예상됩니다.

아시아태평양은 고령화 인구의 급증, 의료 인프라에 대한 투자 증가, 개인 맞춤형 의료에 대한 수요 증가로 인해 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.

자주 묻는 질문

Q1정밀 종양학 시장 규모는?

A1. 세계 정밀 종양학 시장은 2030년까지 약 1,828억 달러에 달할 것으로 예상됩니다.

Q2정밀 종양학 시장의 성장 전망은?

A2. 세계 정밀 종양학 시장은 2024년부터 2030년까지 연평균 9.0%의 CAGR로 성장할 것으로 예상됩니다.

Q3정밀 종양학 시장의 성장에 영향을 미치는 주요 촉진요인은 무엇인가?

A3. 이 시장의 주요 촉진요인은 기술 발전, 암 환자의 부작용을 최소화하면서 효과적인 결과를 얻기 위한 진단 제품에 대한 수요 증가, 특정 약물 내성 문제에 대한 대응입니다.

Q4. 시장의 주요 부문은?

A4. 정밀 종양학 시장의 미래는 병원 및 진단 검사실, 제약 및 생명공학 기업, 의료 데이터 기업 등 다양한 시장에서의 기회로 인해 유망한 것으로 평가됩니다.

Q5. 시장의 주요 기업은?

A5. 정밀 종양학 주요 기업은 다음과 같습니다.

• Thermo Fisher Scientific
• Invitae
• Qiagen
• Illumina
• Laboratory Corporation
• Exact Sciences
• Rain Oncology
• Strata Oncology
• Xilis
• Variantyx

Q6. 향후 가장 큰 시장 부문은?

A6. Lucintel은 암 조기 개입 및 치료에 대한 수요 증가, 진단 영상 및 검사 기술 향상, 진단 결과에 기반한 맞춤형 의약품에 대한 수요 증가로 인해 진단 분야가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상하고 있습니다.

Q7. 시장에서 향후 5년간 가장 큰 시장이 될 것으로 예상되는 지역은 어디인가?

A7. 아시아태평양은 고령화 인구의 급증, 의료 인프라에 대한 투자 증가, 개인 맞춤형 의료에 대한 수요 증가로 인해 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.

Q8. 보고서 사용자 정의가 가능한가?

A8. 예, Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 정밀 종양학 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 정밀 종양학 시장 동향(2018-2023년)과 예측(2024-2030년)
• 제품 유형별 세계의 정밀 종양학 시장
  • 진단 분야
  • 치료 분야
• 암 종류별 세계의 정밀 종양학 시장
  • 유방암
  • 자궁경부암
  • 전립선암
  • 폐암
  • 기타
• 최종 용도별 세계의 정밀 종양학 시장
  • 병원·진단 검사실
  • 제약·바이오테크놀러지 기업
  • 의료 데이터 기업

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 세계의 정밀 종양학 시장
• 북미의 정밀 종양학 시장
• 유럽의 정밀 종양학 시장
• 아시아태평양의 정밀 종양학 시장
• 기타 지역의 정밀 종양학 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 제품 유형별 세계의 정밀 종양학 시장 성장 기회
  • 암 종류별 세계의 정밀 종양학 시장 성장 기회
  • 최종 용도별 세계의 정밀 종양학 시장 성장 기회
  • 지역별 세계의 정밀 종양학 시장 성장 기회
• 세계의 정밀 종양학 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 정밀 종양학 시장 능력 확대
  • 세계의 정밀 종양학 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Thermo Fisher Scientific
• Invitae
• Qiagen
• Illumina
• Laboratory Corporation
• Exact Sciences
• Rain Oncology
• Strata Oncology
• Xilis
• Variantyx

영문목차

Precision Oncology Trends and Forecast

The future of the global precision oncology market looks promising with opportunities in the hospitals & diagnostic laboratory, pharmaceutical & biotechnology company, and healthcare data company markets. The global precision oncology market is expected to reach an estimated $182.8 billion by 2030 with a CAGR of 9.0% from 2024 to 2030. The major drivers for this market are technological advancements, increasing demand for diagnostic products to have effective results with minimal side effects in cancer patients, and addressing specific drug resistance issues.

Lucintel forecasts that diagnostics is expected to witness highest growth over the forecast period due to rising demand of early intervention and treatment for cancer, improved diagnostic imaging and testing techniques, and demand of personalised medicines based on diagnosis results.

Within this market, hospitals & diagnostic laboratories will remain the largest segment due to global expansion of diagnostics facilities is predicted to accelerate segment growth.

APAC is expected to witness highest growth over the forecast period due to surge in aging population, rising investment in the healthcare infrastructure, and growing demand of personalized medicine in the region.

Emerging Trends in the Precision Oncology Market

The precision oncology market is undergoing rapid changes leading to several new trends that will shape future cancer care delivery. This reflects developments in technology, evolving treatment choices, and changes in health system priorities. It is important for stakeholders who want to stay ahead of this dynamic field by being proactive about leveraging new opportunities to innovate and grow to understand these trends.

• Integration of Artificial Intelligence (AI) and Machine Learning: Precision oncology is gradually incorporating AI and machine learning techniques that enhance the diagnosis's accuracy as well as treatment planning process. AI algorithms are capable of interrogating large volumes of information from sequencing, medical records, or imaging studies; they can then identify patterns associated with patient outcomes predictions. Consequently, identification of actionable mutations becomes more precise hence personalizing patient recommendations on best treatments according to their genotypes/phenotypes improves their stratification depending on therapeutic options available for them on any occasion within their diseases' progression. In parallel, AI-driven tools have enabled optimization of clinical trial design processes as well as bettering development procedures for drugs which has increased focus on specifics during therapeutically successful targeted therapies.
• Expansion of Genomic Profiling and Next-Generation Sequencing (NGS): Genomic profiling and NGS are increasingly employed to provide comprehensive insights into tumor genetics. By sequencing a range of genetic mutations, this evolution paves way for personalized therapy hence more targeted treatment approaches. Technological advances in NGS have reduced both cost per sample as well as turnaround time since that has made genomic analysis feasible at very large number of medical centers. More applications for NGS have prompted the development of new-targeted therapies as well as companion diagnostics designed specifically for individual genetic profiles.
• Rise of Personalized Immunotherapies: Precision oncology is currently marked by the rise in customized immunotherapy. These utilize immune cells in the patient's body to fight cancer based on its unique characteristics. As scientists understand better which antigens are associated with tumors, they will be able to develop more effective and person-specific immunotherapies. In vivo responses against diverse mutants evolving to meet precision requirements include personalized vaccines, adoptive cell therapies, checkpoint inhibitors etc., all considered within specific genomics/molecular contexts that enhance therapeutic relevance while minimizing adverse events.
• Development of Liquid Biopsies: Liquid biopsies are emerging as strong trends within precision oncology since they provide a non-invasive approach for cancer detection or monitoring purposes. Liquid biopsies can be used to monitor tumor dynamics, genetic alterations through circulating tumor DNA (ctDNA) among other biomarkers present in blood samples obtained from patients suffering from cancer without having to conduct tissue biopsy. Cancer can thus be detected early; minimum residual disease traced during chemotherapy and efficacy treatment evaluated through such tests whereby liquid biopsy development process allows tailored care programs based on how different patients respond towards same therapy regimens.
• Health Data Integration and Interoperability Focus: The convergence of health data using various precision oncology strategies is one of the five important trends. The comprehensive profiling of patients from genomics, EHRs, and other sources to create a unified dataset is being attempted. This information integration enhances precise diagnosis, personalized treatment planning, outcome tracking. In oncology; this enhances evidence-based decision-making while also contributing to large-scale research in support of treatment protocols improvements.

The precision oncology market is evolving with emergence trends like AI & machine learning integration, genomic profiling expansion, personalized immunotherapies growth, liquid biopsy development & health data focus. This illustrates steps forward in technology and targeted medicine that lead to innovation as well as better patient outcomes. Stakeholders who take advantage of these developments are therefore more likely to drive the progress of precision oncology in line with changing needs for cancer patients.

Recent Developments in the Precision Oncology Market

Significant advancements in technology, treatment modalities, and research are reflected in recent developments within the precision oncology market. These changes are revolutionizing cancer care by making it possible for treatments that are tailored on unique genetic profiles thus becoming more personalized and efficient. Notably among them include innovations such as genomic technologies progressions; targeted therapies as well as data fusion which have collectively propelled precision oncology into higher heights with improved clinical outcomes.

• Improvements in Next-Generation Sequencing (NGS): There have been notable advancements made with next-generation sequencing (NGS) including enhanced speed accuracy and cost effectiveness. This type of growth now allows full genomic profiling across tumors allowing for identification of a broad range of genetic mutations or alterations improvement has allowed for more precise therapy choices for patients [1]. It was once regarded as science fiction but now is the reality of targeted therapy that aids in patient stratification, development of targeted therapy and even better outcomes. The significance of NGS cannot be overemphasized for its role in moving precision oncology forward since it enhances diagnostic ability while offering therapeutic options.
• Emergence of Targeted Therapies: An example of major progressions in precision oncology is the introduction of targeted therapies. In order to attack genetic mutations or alterations found specifically on tumors, these drugs have been formulated so that they are more effective and non-toxic than other options. Recent developments include approval of new medicines which target specific cancers and identification of novel "druggable" targets [6]. As indicated by recent studies, patients with various types of cancer have improved chances for survival as a result of targeted therapies making them a central pillar in modern precision oncology.
• Progress in Personalized Immunotherapy: There has been advancement towards personalized immunotherapy involving treatment targeting individual tumor profiles and immune responses. One such innovation is the personalization cancer vaccines, adoptive cell therapies (e.g., CAR-T cell therapy), and checkpoint inhibitors. These all function by increasing immune system's recognition to cancer cells through exploiting specific genetic or molecular features on the tumor [7]. Previously hard-to-treat malignancies are now being treated with personalized immunotherapy offering hope for patients who had been deemed untreatable.
• Growth of Liquid Biopsies: They have become an important element of precision oncology, creating a non-invasive way for cancer diagnosis, monitoring and also assessment of therapy progress. In the form of analyzing blood samples to detect circulating tumor DNA (ctDNA) or other biomarkers, it provides real-time information about tumor dynamics and genetic changes. The development has resulted in higher sensitivity and specificity thus making liquid biopsies crucial for early cancer detection, minimal residual disease tracking as well as selection of treatment modalities.
• Integration of Artificial Intelligence (AI): Diagnostic accuracy and treatment planning are being improved through integration of artificial intelligence (AI) into precision oncology. Large data sets derived from genome sequencing, imaging studies, and electronic health records are analyzed by AI algorithms. This application assists in identifying actionable mutations, predicting patient outcomes and optimizing treatment strategies among others. AI-based solutions are accelerating drug development processes as well as making clinical trials more efficient thus contributing significantly in enhancing precision oncology techniques on a global scale.

Precision oncology market has seen several transformations which include NGS improvements, targeted therapies introduction, personalized immunotherapy options availability, incursion by liquid biopsies and integration with AI technologies amongst others. These innovations have improved diagnostic capabilities and therapeutic interventions thereby leading to the provision of more personalised care approaches that give better results. Such developments will push for further advancements within this field hence improving the outcomes for patients under precision oncology care.

Strategic Growth Opportunities for Precision Oncology Market

There are many strategic growth opportunities within the precision oncology market across different applications due to technological advancements as well as increasing focus on personalized medicine. Taking advantage of these chances can help stakeholders expand their business presence while fostering innovation simultaneously. Some key applications include genomic profiling, targeted therapies, immunotherapy, liquid biopsies, and data integration. It is through exploring these opportunities that one can have a clear understanding of where to make investments or developmental projects.

• Genomic profiling: Precision Oncology has a growth opportunity in genomic profiling, allowing for comprehensive analysis of tumor genetic profile. developments in sequencing technologies and bioinformatics are increasing the precision and speed at which genomic profiling is carried out. Genomic profiling identifies specific genetic mutations or alterations that aid in the development of targeted therapies. This opportunity aligns with the rising demand for more precise cancer care and individualized medicine thus making it an excellent area to invest and develop in.
• Targeted therapies: Another growth opportunity lies in targeted therapy development and commercialization. Designer drugs for selective targeting of specific genetic mutations or molecular pathways involved in carcinogenesis. The latest advances in drug discovery and development have led to the emergence of new types of targeted therapy having higher efficiency rates coupled with decreased side effects. Investing in researches related to targeted therapy increases opportunities for treatment discoveries hence improving patients' lives when dealing with precision oncology diseases.
• Immunotherapy: There are prospects to be exploited within immunotherapy especially on personalized as well as targeted approaches being used currently. These breakthroughs comprise tailored checkpoint inhibitors, personalized cancer vaccines and adoptive cell treatments depending on individual tumor profiles as well as immune responses. Thus, there is room for developing new drugs, enhancing current ones or expanding their use across different tumors under immunotherapy field advancement .The above mentioned is a perfect example of how this domain prioritizes bringing the power of immune system against malignancy
• It is a fact that liquid biopsy development represents a remarkable chance for growth in precision oncology. Biomarkers analysis of blood samples eliminates the need of invasive methods in diagnosing and monitoring cancer conditions. The increased sensitivity and accuracy of liquid biopsies have made them more suitable for early cancer screening, treatment follow-up and individualized therapy planning. Therefore, investing in technologies and applications of liquid biopsy would provide valuable insights about tumor dynamics and improve management of patients within the scope of precision oncology.
• Health Data Integration: There is a tremendous opportunity for growth by integrating and analyzing health data from different sources such as genomic sequencing, electronic medical records, imaging studies among others. Efforts to harmonize and regularize healthcare information allows better diagnosis, personalized therapy designs, as well as outcome monitoring. It has been facilitated by collaborative platforms and data sharing initiatives that are supporting research at large scale levels with evidence-based decisions making. By investing in health data integration technologies as well as solutions may help advance precision oncology which will lead to improved patient outcomes.

The precision oncology market growth opportunities involve genomic profiling, targeted therapies, immunotherapy, liquid biopsies and health data integration strategies. By focusing on these areas stakeholders can drive innovation increase market presence taking care of emerging challenges posed by cancer. Attempting to capitalize on these opportunities is vital for advancing precision medicine while improving patient outcomes.

Precision Oncology Market Driver and Challenges

Different drivers and challenges shape the precision oncology market impacting its growth an evolution over time. This marketplace landscape depends on various technological advances economic factors along with regulatory considerations among other things. These drivers and challenges must be understood by players to navigate through this market effectively while leveraging opportunities or avoiding obstacles.

The factors responsible for driving the precision oncology market include:

1. Technological Advancements: Improvements in genomic sequencing technology, big data analytics, and artificial intelligence integration are major drivers in the field of precision oncology. For instance, next-generation sequencing (NGS) and advanced bioinformatics tools have enabled a better understanding of genetic information to be used in developing targeted therapies. As such advances allow for more personalized and effective cancer drugs, investment in this market is growing.

2. Rising Demand for Personalized Medicine: The precision oncology market is being driven by the increasing demand for personalized medicine. Patients and doctors alike are looking for treatments that are tailored specifically to their genetic makeup, as well as the unique features of their cancer cells. Precision oncology fulfills this need by creating individual treatment plans based on comprehensive genomic profiling. This shift is promoting innovation and expanding access within precision medicine.

3. Increased Investment in Research & Development: Increased investments in R&D activities are driving progressions within precision oncology space. This includes funding from both private sector investors and governments who promote new technologies therapy options as well as diagnostic means. Thus, increased research and development initiatives drive innovations thereby enhancing market growth through introduction of cutting-edge solutions into a highly dynamic industry.

4. Growing Focus on Early Cancer Detection: Increased importance has been placed on early detection of cancer which results in a demand for precision oncology solutions. Early diagnosis enhances faster interventions since it allows early diagnosis by use of liquid biopsies or other modern-day imaging techniques. The move towards earlier detection improves cancer's curability rates; therefore, increasing the size of markets served by specific medical practitioners dealing with cancers where precision therapeutics applies.

5. Collaborations and Partnerships: Research institutions, biotech companies, and healthcare providers are working together on precision oncology. Sharing information, developing technology, and conducting clinical tests amongst other things are some of the ways these collaborations foster innovation and expand the scope of accurate cancer treatment. Alliances aimed at fostering collaboration that allows for quick advances in the market contribute significantly to its growth.

Challenges in the precision oncology market are:

1. The High Expenses of Precision Oncology Technologies: One challenge to market growth is the high costs that come with employing precision oncology technologies such as genomic sequencing and targeted therapies. The accessibility and affordability of advanced technologies can be limited by the cost involved in their development and implementation for some patients and healthcare systems. Ensuring broader adoption and market expansion require addressing these cost-related challenges.

2. Regulatory And Compliance Issues: Regulatory and compliance barriers associated with precision oncology technologies are a constraint for market growth. Approval and commercialization of new technologies requires strict adherence to regulations, safety, and efficacy concerns. Precision oncology solutions may be delayed or not become available as navigating the regulatory environment is usually difficult and time-consuming.

3. Data Privacy And Security Concerns: The issue of data privacy and security ensues in the handling and integration of large amounts of health information in precision oncology. Trust building is important through patient information safeguarding following the rules on data protection. Precisely therefore, successful implementation, future spread of precision oncology technologies can only be achieved if this matter were to be addressed appropriately.

Technological advancements; increased demand for personalized medicine; rising investment in R&D focus on early cancer detection; collaborations are factors driving the precision oncology market Challenges include high costs; regulatory and compliance issues; data privacy concerns These factors must be understood if one is to navigate the market, exploit opportunities for growth, succeed in this ever-changing sphere of precision oncology.

List of Precision Oncology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies precision oncology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the precision oncology companies profiled in this report include-

• Thermo Fisher Scientific
• Invitae
• Qiagen
• Illumina
• Laboratory Corporation
• Exact Sciences
• Rain Oncology
• Strata Oncology
• Xilis
• Variantyx

Precision Oncology by Segment

The study includes a forecast for the global precision oncology by product type, cancer type, end use, and region.

Precision Oncology Market by Product Type [Analysis by Value from 2018 to 2030]:

• Diagnostics
• Therapeutics

Precision Oncology Market by Cancer Type [Analysis by Value from 2018 to 2030]:

• Breast Cancer
• Cervical Cancer
• Prostate Cancer
• Lung Cancer
• Others

Precision Oncology Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Healthcare Data Companies

Precision Oncology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Precision Oncology Market

The precision oncology market has seen significant growth in recent years. This is mainly due to the increased understanding of cancer genomics and the rising demand for personalized treatment options. Precision oncology seeks to use a patient's genetic make-up to determine treatment options, making them more effective and less harmful. The latest advances in this field show advances in genomic technology, targeted therapies, and data analytics that enable more precise diagnosis and treatment of cancers. In these advancements, key players including China, Germany, India, Japan, and the United States have all had different strategies that helped shape their respective paths towards precision oncology.

• United States: The United States has been experiencing substantial progress in terms of precision oncology. This is most evident through its genomics programs as well as the development of targeted therapy initiatives. Recent developments such as Next-Generation Sequencing (NGS) used for comprehensive profiling of tumors have allowed for better identification of actionable mutations. FDA approval for a number of new targeted therapies and companion diagnostics that match treatments with particular gene alterations found among cancer patients adds weight on this point Furthermore; there has been an increasing amount of attention paid to incorporating artificial intelligence (AI) and machine learning techniques into oncological practice to enhance accuracy in diagnosis and treatment selection. Personalized vaccines and immunotherapies are also being pioneered by US researchers.
• China: China has made remarkable strides in precision oncology through considerable investments in research and development (R&D). Some examples include expansion of genomic databases plus adoption advanced sequencing technologies which have facilitated large-scale studies on cancer in the country. For instance, Chinese firms are now heavily involved in developing targeted therapies as well as immunotherapies specifically suited for the Asian genetic makeup . The integration of precision oncology into public health systems thereby enhancing access to sophisticated diagnostics and treatment modalities for cancer is also underway across China . Such collaborations between Chinese academic institutions or biotech companies worldwide are expediting refinement and release of precision oncology solutions.
• Germany: In Germany has been the leader in advancing precision oncology with substantial progress in genomic research and personalized medicine. The implementation of comprehensive cancer genome sequencing in clinical practice is a recent example, which provides detailed individual tumor profiles. In addition to that, German scientists are focusing on developing targeted therapies as well as personalized treatment regimens guided by genetic data. Data exchange and integration are also specifically attuned to Germany where it was at the forefront of efforts to create large multi-national cancer research databases. This includes new drug delivery approaches and combination therapies being developed by German biotech companies that improve the accuracy of cancer care.
• India: The precision oncology market in India has witnessed increased focus on genomics and personalized medicine aimed at improving cancer care. There have been a number of notable developments such as the establishment of genomic sequencing facilities plus introduction targeted therapies in key cancer centers across India. For example, Indian researchers are studying common mutations that exist within their population with the purpose of finding remedies for them. As part of its public health system development initiatives it is striving to make sophisticated diagnostics and treatments available for wider population . International relationships between Indian institutions and partners have contributed significantly to faster growth in research work on precision oncology practices.
• Japan: Japan is making great strides in precision oncology, particularly with advances in genetic medicine and precision therapy. These include recent developments such as the integration of comprehensive genomic profiling into clinical practice and the approach to design novel targeted therapies informed by genetic and epigenetic mutations. Japanese scientists are also looking at ways through which precision oncology can be applied in early detection of cancers as well as personalized treatment plans. Innovative drug delivery systems and precise immunotherapies are highly focused areas for development. Japan's partnership with global research networks and its investment in advanced cancer research have led to significant breakthroughs in precision oncology.

Features of the Global Precision Oncology Market

Market Size Estimates: Precision oncology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Precision oncology market size by product type, cancer type, end use, and region in terms of value ($B).

Regional Analysis: Precision oncology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, cancer types, end uses, and regions for the precision oncology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the precision oncology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the precision oncology market size?

Answer: The global precision oncology market is expected to reach an estimated $182.8 billion by 2030.

Q.2 What is the growth forecast for precision oncology market?

Answer: The global precision oncology market is expected to grow with a CAGR of 9.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the precision oncology market?

Answer: The major drivers for this market are technological advancements, increasing demand for diagnostic products to have effective results with minimal side effects in cancer patients and addressing specific drug resistance issues.

Q4. What are the major segments for precision oncology market?

Answer: The future of the precision oncology market looks promising with opportunities in the hospitals & diagnostic laboratory, pharmaceutical & biotechnology company, and healthcare data company markets.

Q5. Who are the key precision oncology market companies?

Answer: Some of the key precision oncology companies are as follows:

• Thermo Fisher Scientific
• Invitae
• Qiagen
• Illumina
• Laboratory Corporation
• Exact Sciences
• Rain Oncology
• Strata Oncology
• Xilis
• Variantyx

Q6. Which precision oncology market segment will be the largest in future?

Answer: Lucintel forecasts that diagnostics is expected to witness highest growth over the forecast period due to rising demand of early intervention and treatment for cancer, improved diagnostic imaging and testing techniques, and demand of personalised medicines based on diagnosis results.

Q7. In precision oncology market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to surge in aging population, rising investment in the healthcare infrastructure, and growing demand of personalized medicine in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the precision oncology market by product type (diagnostics and therapeutics), cancer type (breast cancer, cervical cancer, prostate cancer, lung cancer, and others), end use (hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, and healthcare data companies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Precision Oncology Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Precision Oncology Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Precision Oncology Market by Product Type
  • 3.3.1: Diagnostics
  • 3.3.2: Therapeutics
• 3.4: Global Precision Oncology Market by Cancer Type
  • 3.4.1: Breast Cancer
  • 3.4.2: Cervical Cancer
  • 3.4.3: Prostate Cancer
  • 3.4.4: Lung Cancer
  • 3.4.5: Others
• 3.5: Global Precision Oncology Market by End Use
  • 3.5.1: Hospitals & Diagnostic Laboratories
  • 3.5.2: Pharmaceutical & Biotechnology Companies
  • 3.5.3: Healthcare Data Companies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Precision Oncology Market by Region
• 4.2: North American Precision Oncology Market
  • 4.2.1: North American Precision Oncology Market by Product Type: Diagnostics and Therapeutics
  • 4.2.2: North American Precision Oncology Market by End Use: Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Healthcare Data Companies
• 4.3: European Precision Oncology Market
  • 4.3.1: European Precision Oncology Market by Product Type: Diagnostics and Therapeutics
  • 4.3.2: European Precision Oncology Market by End Use: Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Healthcare Data Companies
• 4.4: APAC Precision Oncology Market
  • 4.4.1: APAC Precision Oncology Market by Product Type: Diagnostics and Therapeutics
  • 4.4.2: APAC Precision Oncology Market by End Use: Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Healthcare Data Companies
• 4.5: ROW Precision Oncology Market
  • 4.5.1: ROW Precision Oncology Market by Product Type: Diagnostics and Therapeutics
  • 4.5.2: ROW Precision Oncology Market by End Use: Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Healthcare Data Companies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Precision Oncology Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Precision Oncology Market by Cancer Type
  • 6.1.3: Growth Opportunities for the Global Precision Oncology Market by End Use
  • 6.1.4: Growth Opportunities for the Global Precision Oncology Market by Region
• 6.2: Emerging Trends in the Global Precision Oncology Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Precision Oncology Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Precision Oncology Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Thermo Fisher Scientific
• 7.2: Invitae
• 7.3: Qiagen
• 7.4: Illumina
• 7.5: Laboratory Corporation
• 7.6: Exact Sciences
• 7.7: Rain Oncology
• 7.8: Strata Oncology
• 7.9: Xilis
• 7.10: Variantyx